License and Supply Agreement - Lupin Ltd

Code BSE: 500257 NSE:

The Company has entered into a License and Supply Agreement with Zentiva, k.s., for commercialization of Lupin’s biosimilar Certolizumab Pegol. Lupin will be responsible for the development, manufacturing and supply of the product within the agreed territories, whereas, Zentiva will oversee commercialization activities in Europe and CIS markets, where it will leverage its extensive European commercial infrastructure and regulatory expertise. Lupin will undertake commercialization in the remaining regions, including USA and Canada.